MORPHOSYS AG (MOR.DE) Stock Price & Overview
FRA:MOR • DE0006632003
Current stock price
The current stock price of MOR.DE is 67.25 EUR. Today MOR.DE is down by -0.66%. In the past month the price decreased by -0.52%. In the past year, price increased by 140.44%.
MOR.DE Key Statistics
- Market Cap
- 10.131B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -12.37
- Dividend Yield
- N/A
MOR.DE Stock Performance
MOR.DE Stock Chart
MOR.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MOR.DE. When comparing the yearly performance of all stocks, MOR.DE is one of the better performing stocks in the market, outperforming 99.3% of all stocks.
MOR.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MOR.DE. Both the profitability and financial health of MOR.DE have multiple concerns.
MOR.DE Earnings
On April 29, 2024 MOR.DE reported an EPS of -8.16 and a revenue of 27.54M. The company missed EPS expectations (-115317.26% surprise) and missed revenue expectations (-49.34% surprise).
MOR.DE Forecast & Estimates
12 analysts have analysed MOR.DE and the average price target is 55.59 EUR. This implies a price decrease of -17.34% is expected in the next year compared to the current price of 67.25.
For the next year, analysts expect an EPS growth of 20.86% and a revenue growth -3.33% for MOR.DE
MOR.DE Groups
Sector & Classification
MOR.DE Financial Highlights
Over the last trailing twelve months MOR.DE reported a non-GAAP Earnings per Share(EPS) of -12.37. The EPS decreased by -160.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MOR.DE Ownership
MOR.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 26.73 | 40.051B | ||
| 1AE | ARGENX SE | 26.69 | 39.989B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.659B | ||
| 2X1 | ABIVAX SA | N/A | 8.034B | ||
| ABVX | ABIVAX SA | N/A | 8.018B | ||
| GXE | GALAPAGOS NV | N/A | 1.691B | ||
| GLPG | GALAPAGOS NV | N/A | 1.687B | ||
| NANO | NANOBIOTIX | N/A | 1.326B | ||
| 6IV | INVENTIVA SA | N/A | 981.136M | ||
| IVA | INVENTIVA SA | N/A | 980.098M | ||
| PHIL | PHILOGEN SPA | 17.77 | 649.128M | ||
| GNFT | GENFIT | 846.08 | 431.525M | ||
| FYB | FORMYCON AG | N/A | 329.015M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About MOR.DE
Company Profile
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Company Info
IPO: 1999-03-09
MORPHOSYS AG
Semmelweisstr. 7
Planegg BAYERN DE
Employees: 464
Phone: 4989899270
MORPHOSYS AG / MOR.DE FAQ
What does MOR do?
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. The company is headquartered in Planegg, Bayern and currently employs 464 full-time employees. The firm discovers, develops, and delivers cancer medicines to patients. The company markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
What is the stock price of MORPHOSYS AG today?
The current stock price of MOR.DE is 67.25 EUR. The price decreased by -0.66% in the last trading session.
Does MORPHOSYS AG pay dividends?
MOR.DE does not pay a dividend.
How is the ChartMill rating for MORPHOSYS AG?
MOR.DE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about MORPHOSYS AG (MOR.DE) stock?
12 analysts have analysed MOR.DE and the average price target is 55.59 EUR. This implies a price decrease of -17.34% is expected in the next year compared to the current price of 67.25.
What is the GICS sector and industry of MOR stock?
MORPHOSYS AG (MOR.DE) operates in the Health Care sector and the Biotechnology industry.